ReviewCurrent treatment options in oncology2021
Immunotherapy in Hepatocellular Carcinoma.
Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Identification of pyroptosis and hypoxia related molecular subtypes and a prognostic signature in colorectal cancer.Discover oncology · 2026Article
- Nomograms and an inflammation model predict immunotherapy prognosis in unresectable hepatocellular carcinoma: from survival and response.Frontiers in oncology · 2026Article
- Effect of regorafenib combined with immunotherapy and arterial chemoembolization on the survival of patients with advanced hepatocellular carcinoma: a retrospective study.American journal of translational research · 2025Article
- Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.Journal of hepatocellular carcinoma · 2024Article
- Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.Cancers · 2023Review
- The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.Current oncology (Toronto, Ont.) · 2023Review
- Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.Hepatology international · 2023Article
- CDC23 knockdown suppresses the proliferation, migration and invasion of liver cancer via the EMT process.Oncology letters · 2023Article
- Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.Liver international : official journal of the International Association for the Study of the Liver · 2023Observational
- Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.BMC gastroenterology · 2023Article
- Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma.Cancers · 2023Review
- Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.Frontiers in pharmacology · 2023Review
- Immunotherapies for advanced hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.Frontiers in immunology · 2023Review
- AHSA1 Regulates Hepatocellular Carcinoma Progression via the TGF-β/Akt-Cyclin D1/CDK6 Pathway.Journal of hepatocellular carcinoma · 2023Article
- Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.World journal of transplantation · 2022Review
- Review
- Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?International journal of molecular sciences · 2022Review
- Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
opinion statementPatients with hepatocellular carcinoma (HCC) have been traditionally deprived from highly effective systemic therapy options in the past decades. The multi-targeted tyrosine kinase inhibitor sorafenib, approved in 2008, remained the only treatment option for advanced HCC for over a decade. A number of molecularly targeted therapies such as lenvatinib, regorafenib, cabozantinib, and ramucirumab have significantly widened treatment options in patients with advanced HCC. However, emergence of resistance and long-term toxicity from treatment are barriers to long-term survivorship. Immunotherapy is at the focus of intense research efforts in HCC. Whilst targeting of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte 4 (CTLA-4) is associated with radiologically measurable disease-modulating effects in HCC, monotherapies fell short of demonstrating evidence of significant survival extension in advanced disease. Atezolizumab and bevacizumab were the first immunotherapy regimen to demonstrate clear superiority in improving the survival of patients with unresectable HCC compared to sorafenib, paving the way for immunotherapy combinations. As the treatment landscape of HCC rapidly evolves, with immunotherapy integrating within early- and intermediate-stage disease treatment algorithms, lack of level 1 evidence on sequencing of therapeutic strategies and lack of head-to-head comparisons across immunotherapy combinations will affect prescribing of immunotherapy in routine practice. In the absence of predictive biomarkers, choice of immunotherapy over kinase inhibitors will continue to remain an empirical exercise, guided by balancing anti-tumour efficacy with toxicity considerations in the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.